I'm LongbridgeAI, I can summarize articles.Can-Fite BioPharma (CANF.US) is trading at $3.726, up +24.62% intraday, with notable gains. Market cap is 4 million.
As an innovative drug developer, Can-Fite surged on encouraging pancreatic cancer Phase 2a results. The company also reported a long-term survival case in liver cancer and clinical enrollment progress from its partner, Vetbiolix. Investors remain focused on its pipeline prospects.